Cerebrospinal fluid erythropoietin (EPO) in amyotrophic lateral sclerosis

This publication has 21 references indexed in Scilit:

• Erythropoietin in the cerebrospinal fluid in neurodegenerative diseases
  Neuroscience Letters, 2006
• Axonal damage markers in cerebrospinal fluid are increased in ALS
  Neurology, 2006
• Erythropoietin: Novel Approaches to Neuroprotection in Human Brain Disease
  Metabolic Brain Disease, 2004
• Enhanced expression of erythropoietin in the central nervous system of SOD1G93A transgenic mice
  Brain Research, 2004
• Erythropoietin: a candidate compound for neuroprotection in schizophrenia
  Molecular Psychiatry, 2003
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial
  Molecular Medicine, 2002
• Erythropoietin crosses the blood–brain barrier to protect against experimental brain injury
  Proceedings of the National Academy of Sciences, 2000
• El Escorial revisited: Revised criteria for the diagnosis of amyotrophic lateral sclerosis
  Amyotrophic Lateral Sclerosis, 2000
• Erythropoietin and Erythropoietin Receptor in the Developing Human Central Nervous System
  Pediatric Research, 1998
• Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain‐Barré syndrome
  Muscle & Nerve, 1991